Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Euromelanoma

- PMLiVE

Eli Lilly and Almirall’s lebrikizumab shows sustained improvements in atopic dermatitis

The IL-13 inhibitor improved the symptoms of atopic dermatitis for up to two years

- PMLiVE

Almirall and EpimAb Biotherapeutics enter $210m bispecific antibody partnership

The agreement gives Almirall access to EpimAb’s FIT-Ig drug discovery platform

- PMLiVE

Almirall receives CHMP recommendation for lebrikizumab in atopic dermatitis

The drug has been recommended as a treatment option for adult and adolescent patients

- PMLiVE

World Atopic Eczema Day 2023: Almirall unveils awareness campaign

The inflammatory skin disease is estimated to affect 4.4% of adults in the EU

- PMLiVE

Almirall’s Ilumetri shown to improve well-being of patients with plaque psoriasis

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Almirall launches mini-series to highlight impact of psoriasis on patient well-being

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Almirall survey reveals limited knowledge of most common precancerous skin condition

Up to 80% of squamous cell carcinomas develop from actinic keratosis lesions

- PMLiVE

Almirall and CRG announce non-melanoma skin cancer research collaboration

The partners will jointly develop novel preclinical models to identify new treatments for NMSC

- PMLiVE

Almirall and Eli Lilly’s lebrikizumab shows continued improvement in atopic dermatitis

The common inflammatory skin disease affects over 4% of adults in the EU

- PMLiVE

Almirall becomes first to assess well-being as primary endpoint in dermatology study

Almost 77% of psoriasis patients report that the condition negatively affects their well-being

- PMLiVE

Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD

The common inflammatory skin disease affects over 4% of adults in the EU

- PMLiVE

Almirall set to participate in Innovative Medicines Initiative’s FACILITATE project

The project aims to return clinical trial data to participants, readying it for reuse in future research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links